Mesa Labs reports Q2 EPS 71c, consensus 81c.

Reports Q2 revenue $25.5M, consensus $26.01M. "Performance was steady in the second quarter with organic revenues growth of 3%, and no meaningful change to gross margin percentage, when excluding Packaging for both items. Cold Chain Monitoring revenues rebounded from a poor first quarter, but we are not growing profitability in line with revenues in the way we had planned. Strategically, the acquisition of Gryos Protein Technologies Holding AB on October 31, 2019, adds an exciting high growth vector for the Company, deepens our commitment to serving the Biopharmaceutical Development market with mission critical quality control instruments and consumables, and adds a tremendous influx of talent to the overall Mesa team. For additional details on the GPT Acquisition, see our October 31st press release and investor presentation. With our recent capital raise of over $240M and the acquisition of GPT at $180M, we retain enough capital to continue our acquisition program in the near term."